CXCR4 and familial pancreatic carcinoma: A unique anti-PD-L1/CXCR4 bispecific nanobody could successfully penetrate the tumor tissues in a xenograft mouse model and inhibit the growth of pancreatic cancer cells much better than the combination therapy using anti-PD-L1 and anti-CXCR4 nanobodies (158).